09 January 2018
IntegraGen reports 2017 revenue and cash position
IntegraGen today announces its unaudited sales revenue for the 2017.
09 January 2018
IntegraGen and GoPath Laboratories sign licensing agreement for miR-31-3p test in North America
IntegraGen and GoPath Laboratories announced today the signing of a non-exclusive licensing agreement allowing GoPath to develop and provide a test based on IntegraGen’s proprietary miR-31-3p biomarker to physicians in the United States and Canada. The test will complement GoPath’s specialized molecular diagnostic testing portfolio for cancer and enable clinicians to (…) »
21 November 2017
Bernard Courtieu invited to speak on bioinformatic tools during CRCHUM Conference in Montreal
IntegraGen’s CEO, Bernard Courtieu has been invited to speak at the University of Montreal Hospital Research Centre (CRCHUM) on November 27, 2017 as a part of their CRCHUM Conference series. Dr. Courtieu will be speaking on the topic “From research to routine clinical practice: bioinformatic tools are permitting (…) »
11 November 2017
IntegraGen to attend the Jefferies 2017 London Healthcare Conference
IntegraGen will participate in The Jefferies 2017 London Healthcare Conference taking place 15 and 16 November 2017 in London, UK.
The Jefferies Conference is the largest healthcare-dedicated conference in Europe with over 350 participating companies, 1,400 attendees and 3,400 business-to-business and investor meetings. The event will feature (…) »
30 October 2017
IntegraGen receives Galien MedStartUp award for collaboration with The Solution Lab on ICE software
IntegraGen today announced that it received the 2017 Galien MedStartUp award for “Best Collaboration for a Breakthrough Therapy or Diagnosis” during the recent MedStartUp Days conference held in New York City. IntegraGen was presented the award based on its collaboration with The Solution Lab, a non-profit organization which (…) »
09 October 2017
IntegraGen announces miR-31-3p publication in Oncotarget
IntegraGen announces that results from an analysis of miR-31-3p expression in tumor samples from patients enrolled in the NEW EPOC clinical trial have been published online in Oncotarget. The paper entitled “Association between miR-31- 3p expression and cetuximab efficacy in patients with KRAS wild-type metastatic colorectal cancer: a (…) »
28 September 2017
IntegraGen Reports Financial Results for 1st Half of 2017
07 September 2017
IntegraGen Announces CE-IVD Marking of miRpredX 31-3p Kit
IntegraGen today announced the CE-IVD marking and commercial launch of its miRpredX 31-3p test kit in the E.U., the first positive theranostic test for patients with metastatic colorectal cancer.
Click here for press release
04 August 2017
IntegraGen to participate in the 17th Large & Midcap Event – Paris
IntegraGen will be participating the 17th Large and Midcap Event – Paris being held on 6 and 7 October 2017 at the Palais Brongniart.
28 April 2017
Notice of publication of annual financial report
IntegraGen informs its shareholders and the financial community that its 2016 Annual Financial Report has been filed with the AMF.
